Expertise in
10
conditions

Dr. Thomas Gergel

Radiation Oncology
Guthrie Robert Packer Hospital
1 Guthrie Sq, 
Sayre, PA 
Expertise in
10
conditions
Guthrie Robert Packer Hospital
1 Guthrie Sq, 
Sayre, PA 

Overview

Thomas Gergel is a Radiation Oncologist in Sayre, Pennsylvania. Dr. Gergel is highly rated in 10 conditions, according to our data. His top areas of expertise are Posterior Fossa Tumor, Lung Cancer, Pleuropulmonary Blastoma, and Oral Squamous Cell Carcinoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Radiation Oncology

Licenses

Radiology in PA

Hospital Affiliations

Corning Hospital
Our Lady Of Lourdes Memorial Hospital, Inc
Robert Packer Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Guthrie Robert Packer Hospital
1 Guthrie Sq, Sayre, PA 18840
Other Locations
Guthrie Corning Cancer Center
2 Guthrie Dr, Corning, NY 14830

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: March 16, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Radiation, Procedure, Other
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

3 Total Publications

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Journal: International journal of radiation oncology, biology, physics
Published: November 30, 2016
Similar Doctors
Expertise in
15
conditions
Dr. Chi Tsang
Radiation Oncology
Expertise in
15
conditions
Dr. Chi Tsang
Radiation Oncology

Arnot Health

600 Roe Ave, 
Elmira, NY 
 (7.6 miles away)
607-737-8100
Languages Spoken:
English
See accepted insurances

Chi Tsang is a Radiation Oncologist in Elmira, New York. Dr. Tsang is highly rated in 15 conditions, according to our data. His top areas of expertise are Anal Cancer, Small Cell Lung Cancer (SCLC), Angiosarcoma, and Pleuropulmonary Blastoma.

Expertise in
12
conditions
Dr. Omar Yumen
Radiation Oncology
Expertise in
12
conditions
Dr. Omar Yumen
Radiation Oncology

Guthrie Corning Cancer Center

2 Guthrie Dr, 
Corning, NY 
 (0.1 miles away)
607-937-3100
Languages Spoken:
English
See accepted insurances

Omar Yumen is a Radiation Oncologist in Corning, New York. Dr. Yumen is highly rated in 12 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Breast Cancer, and Pleuropulmonary Blastoma.

Expertise in
16
conditions
Dr. Rashid Haq
Radiation Oncology
Expertise in
16
conditions
Dr. Rashid Haq
Radiation Oncology

United Health Services Hospitals

30 Harrison St, 
Johnson City, NY 
 (51.8 miles away)
607-763-8181
Languages Spoken:
English
See accepted insurances

Rashid Haq is a Radiation Oncologist in Johnson City, New York. Dr. Haq is highly rated in 16 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Familial Prostate Cancer, Prostate Cancer, and Oligodendroglioma.

Frequently Asked Questions about Dr. Thomas Gergel

How do I make an appointment with Dr. Thomas Gergel?

You can book an appointment with Dr. Thomas Gergel by calling their office at 570-887-4048. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Gergel a top-rated expert for Posterior Fossa Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Gergel is classified as an Distinguished expert for Posterior Fossa Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Gergel specialize in?

While Dr. Thomas Gergel is a Radiation Oncology, they have specific expertise in Posterior Fossa Tumor, Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Thomas Gergel participate in research or clinical trials?

Yes. Dr. Thomas Gergel has published 3 articles and abstracts on conditions like Posterior Fossa Tumor. You can view a list of Dr. Thomas Gergel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas Gergel accept my insurance?

Dr. Thomas Gergel accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 570-887-4048 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gergel's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile